BRAVE 4: Prasugrel and Bivalirudin vs. Clopidogrel and Heparin in STEMI Patients.
On the same coverage of acc 14 is supported by jensen pharmaceuticals incorporated i’m peter block here at the acc annual meeting in washington dc for on the scene one of the questions that came out of the late-breaking clinical trials is what anticoagulant regimen is in fact superior i’m here with gerhardt we got from germany your hut you did a trial tell me what this
Trial is about and what it was that you did to these patients it was a trial in steamy patients which came acutely to the cath lab patients which were undergoing primary pci and we compared two regimens one was the combination of prasugrel and b value dean to novel drugs won a nobel antiplatelet and the other an oval anti coghlan drug both have 11 a recommendations by
The european and american guidelines and this was compared with a classic combination with clopidogrel and heparin which we use since years now it seems to me that most stemi patients in the united states at least before this trial were given by val rudin is that correct yes yes but the combination with brazil grail is a new option and theoretically and intuitively
This is the better way to treat patients okay since it’s intuitively the better way to treat patients what in fact happened in your trial what in fact happened in our trial which unfortunately had to stir to be stopped early but we didn’t see any difference we could combine that clinical outcome including michael infarctions cardiac deaths and bleeding and urgent
Revascularization and there was virtually no difference between them both groups okay so is that it was stopped because of futility that they could the end point or why was a style it was slower enrollment the study was sponsored by the institutions not by the industry and that made us that we that we didn’t have the progress to enroll patients okay amount okay so
The bottom line here is that there is only no difference in the two groups as far as the numbers have a word that you had together so for everybody out there tell me what you think the take-home message is here from this trial what did you learn we learned that the combination of noble drugs which proceeded have superior results in individual trials not necessarily
Give more benefit if you combine them in the patients that they are recommended to take them okay so there you have it for new novel anticoagulants thank you doctor ricard you
Transcribed from video
ACC.14 | BRAVE 4 By American College of Cardiology Video Archive 2
